1-6 of 6
Anne Quillet-Mary, PhD
Close
Sort by
Journal Articles

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Anne Calleja, Sandra De Barros, Camille Vinson, PharmD, Caroline Protin, MD, Lucie Oberic, MD, Fanny Gallais, Melanie White-koning, Etienne Chatelut, Christian Recher, MD PhD, Sarah Cadot, PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Fabien Despas, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3960.
https://doi.org/10.1182/blood-2018-99-116532
Published: 2018
Journal Articles

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Leylah M. Drusbosky, PhD, Aneel Paulus, MD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Ansu Kumar, MS, Neeraj Kumar Singh, B.Tech, Yashaswini Ullal, BE, Priyanka Bhargav, BE, Humera Azam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Christopher R. Cogle, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4278.
https://doi.org/10.1182/blood.V130.Suppl_1.4278.4278
Published: 2017
Journal Articles

Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach

Loic Ysebaert, MD PhD, Sarah Cadot, PhD, Salim Kanoun, MD, Soleakhena Ken, Christian Recher, MD PhD, François Malgouyres, Sebastien Gadat, Loic Dupre, PhD, Anne Quillet Mary, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2990.
https://doi.org/10.1182/blood.V130.Suppl_1.2990.2990
Published: 2017
Journal Articles

Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients

Martin Gauthier, Florence Durrieu, Michael Peres, MD, Elodie Martin, MSc, Thomas Filleron, PhD, Christian Recher, MD PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1731.
https://doi.org/10.1182/blood.V130.Suppl_1.1731.1731
Published: 2017
Journal Articles

CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo

Loïc Ysebaert, MD PhD, Christian Klein, PhD, Anne Quillet-Mary, PhD
Journal: Blood
Blood (2015) 126 (23): 4157.
https://doi.org/10.1182/blood.V126.23.4157.4157
Published: 2015
Journal Articles

Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?

Loic Ysebaert, MDPhD, Christian Klein, PhD, Anne Quillet-Mary, PhD
Journal: Blood
Blood (2014) 124 (21): 1980.
https://doi.org/10.1182/blood.V124.21.1980.1980
Published: 2014